Elevated second-trimester serum homocyst(e)ine levels and subsequent risk of preeclampsia

Gynecologic and Obstetric Investigation

Volumn 48, Issue 2, 1999, Pages 98-103

  Sorensen, Tanya K ^a   Malinow, M Rene ^b   Williams, Michelle A ^a,c,d   King, Irena B ^d   Luthy, David A ^a  

^a SWEDISH MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Homocyst(e)ine; Hypertension; Preeclampsia; Pregnancy

Indexed keywords

HOMOCYSTEINE;

ADULT; ARTICLE; BLOOD LEVEL; BODY MASS; CONTROLLED STUDY; ELECTROCHEMICAL DETECTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MATERNAL AGE; PARITY; PREECLAMPSIA; PRIORITY JOURNAL; RISK; RISK FACTOR; SECOND TRIMESTER PREGNANCY; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

ADULT; BODY MASS INDEX; FEMALE; HOMOCYSTEINE; HUMANS; MATERNAL AGE; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, SECOND; RISK FACTORS; SOCIOECONOMIC FACTORS;

EID: 0032766921     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000010148     Document Type: Article

References (31)

1. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis JR, Boers GH, Sheahan RG, Israelson B, Uiterwaal CS, Melaedy R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales-Luis AC, Parrot-Rouland FM, Tan KS, Higgins I, Garcon D, Medrano MJ, Candito M, Evans AE, Andria G: Plasma homocysteine as a risk factor for vascular disease. JAMA 1997;277:1775-1781.
2. Mayer EL, Jacobsen DW, Robinson K: Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996;27:517-527.
3. Den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, Vandenbroucke JP, Rosendaal FR: Hyperhomocysteinemia as a risk factor for deep vein thrombosis. N Engl J Med 1996;334:759-762.
4. Rajkovic A, Catalano PM, Malinow MR: Elevated homocyst(e)ine levels with preeclampsia. Obstet Gynecol 1997;90:168-171.
5. Dekker GA, de Vries JIP, Doelitzsch PM, Huijgens PC, von Blomberg BM, Jakobs C, van Geijn HP: Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995;173:1042-1048.
6. Roberts JM, Taylor RN, Goldfen A: Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia. Am J Hypertens 1991;4:700-708.
7. DeGroot CJM, O'Brien TJ, Taylor RN: Biochemical evidence of impaired trophoblastic invasion of decidual stroma in women destined to have preeclampsia. Am J Obstet Gynecol 1996;175:24-29.
8. Walsh SW, Michael JB, Allen NH: Placental prostacyclin production in normal and toxemia pregnancies. Am J Obstet Gynecol 1985;151: 110-115.
9. Everett RB, Worly RJ, MacDonald PC; Chand S, Gant NF: Vascular reactivity to angiotensin II in human pregnancy. Semin Perinatol 1978; 2:3-13.
10. Sorensen TK, Williams MA, Zingheim RW, Clement SJ, Hickok DE: Elevated second-trimester human chorionic gonadotropin and subsequent pregnancy-induced hypertension. Am J Obstet Gynecol 1993;169:834-888.
11. Lockwood CJ, Peters JH: Increased plasma levels of ED1+ cellular fibronectin precede the clinical signs of preeclampsia. Am J Obstet Gynecol 1990;162:358-362.
12. Lazarchick J, Stubbs TM, Romcin L, VanDorsten JP, Loadholt CB: Predictive value of fibronectin levels in normotensive gravid women destined to become preeclamptic. Am J Obstet Gynecol 1996;154:1050-1052.
13. American College of Obstetricians and Gynecologists: Management of Preeclampsia. Tech Bull 19, 1986.
14. Malinow RM, Sexton G, Averbuch M, Grossman M, Wilson D, Upson B: Homocyst(e)inemia in daily practice: Levels in coronary artery disease. Coron Artery Dis 1990;1:215-220.
15. Hsieh CC, Maisonneuve P, Boyle P, Macfarlane GJ, Robertson C: Analysis of quantitative data by quantiles in epidemiologic studies: Classification according to cases, noncases or all subjects. Epidemiology 1991;2:137-140.
16. Mantel N: Chi-square tests with one degree of freedom: Extensions of the Mantel-Haenszel procedure. J Am Stat Assoc 1963;58:690-700.
17. Rothman K: Modern Epidemiology. Boston, Little-Brown, 1986.
18. Greenland S: Modeling and variable selection in epidemiologic analysis. Am J Publ Health 1989;79:340-349.
19. Stampfer MJ, Malinow M, Willett W, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH: A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-881.
20. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilckens B, Pyeritz RE, Andria G, Boers GH, Bromberg IL, Cerone R: The natural history of homocystinuria due to cystathione β-synthase deficiency. Am J Hum Genet 1985;37:1-31.
21. Daubner SC, Matthews RG: Purification and properties of methylenetetrahydrofolate reductase from pig liver. J Biol Chem 1982;37:140-145.
22. Moghadasian MH, McManus BM, Frohlich JJ: Homocysteine and coronary artery disease. Arch Intern Med 1997;157:2299-2308.
23. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP: A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nature Genet 1995;10:111-113.
24. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R: Relation between folate status, a common mutation in methylenetetrahydrofolate reductase and plasma homocysteine concentrations. Circulation 1996;93:7-9.
25. Tucker KL, Selub J, Wilson PWF, Rosenberg IH: Dietary intake pattern relates to plasma folate and homocysteine concentrations in the Framingham Heart Study. J Nutr 1996;126: 3025-3031.
26. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274:1049-1057.
27. Mills JL, McPartlin JM, Kirke PN, Lee YJ, Conley MR, Weir DG, Scott JM: Homocysteine metabolism in pregnancies complicated by neural tube defects. Lancet 1995;345:149-151.
28. Sohda S, Arinami T, Hamada H, Yamada N, Hamaguchi H, Kubo T: Methylenetetrahydrofolate reductase polymorphism and preeclampsia. J Med Genet 1997;34:525-526.
29. Stamler JS, Osborne J, Jaraki O, Rabbani LE, Mullins M, Singel D, Lascalzo J: Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993;91: 308-318.
30. Harpel PC, Chang VT, Broth W: Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: A potential biochemical link between thrombosis, atherogenesis and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 1992;89:10193-10197.
31. Ness RB, Roberts JM: Heterogeneous causes constituting the single syndrome of preeclampsia: A hypothesis and its implications. Am J Obstet Gynecol 1996;175:1365-1370.